Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study

By afschroeder • November 6, 2025

Rogers KA, Yan P, Flinn IW, Stephens DM, Kipps TJ, Larson SM, Martz L, Chen X, Wang H, Hopping E, Bundschuh R, Turkoglu A, Lozanski G, McGarry C, Acosta A, Sechaud R, Baldoni D, Chaudhury A, Whalen J, Hassounah NB, Orwitz N, Otero J, Woo J, Byrd JC. Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study. Clin Cancer Res. 2025 Nov 6:OF1-OF14. doi: 10.1158/1078-0432.CCR-25-0210. Epub ahead of print. PMID: 41194375.

Tags: Hematology/Oncology, Publications

Related Posts

IDH2 mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapy

Hoff FW, Huang Y, Welkie RL, Swords RT, Traer E, Stein EM, Lin TL, Baer MR, Duong VH, Blum WG, Arellano ML, Stock W, Odenike[...]

Real world outcomes of patients with secondary acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation after induction with liposomal daunorubicin-cytarabine (CPX-351)

Ngo D, Kaleka G, Yang D, Mokhtari S, Tinajero J, Marcucci G, Nakamura R, Pullarkat V, Oliai C, Salhotra A. Real world outcomes of patients[...]

First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS <50% and ≥50% Cohorts of the EVOKE-02 Study

Reck M, Patel JD, Gray JE, Reguart N, Cobo M, Pradera JF, Felip E, Cappuzzo F, Garon EB, Neal JW, Mekan S, Safavi F, Fernando[...]